Harry J. Long
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Harry J. Long has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Joel Sorosky
2 shared publicationsBobbie S. Gostout
1 shared publicationBradley J. Monk
1 shared publicationCarl G. Kardinal
Ochsner CCOP
1 shared publicationD. Scott McMeekin
1 shared publicationDaniel A. Nikcevich
Duluth CCOP
1 shared publication
Latest Publications
- 1 December 2007
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 82 (12) , 1566-1574
Prevention, Diagnosis, and Treatment of Cervical Cancer
- 1 December 2007
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 82 (12) , 1566-1574
Prevention, Diagnosis, and Treatment of Cervical Cancer
- 10 July 2007
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (20) , 2966-2974
Management of Metastatic Cervical Cancer: Review of the Literature
This article reviews the English-language literature concerning chemotherapy for advanced, recurrent, or metastatic cervix carcinoma. Specifically, it reviews the available literature for active single agents, doublets, triplets, and multiple drug combination chemotherapy. Until recently, single-agent cisplatin was the drug of choice in metastatic cervix cancer. Various doublets, triplets, and quartlets have been reported to have higher objective response rates than single-agent cisplatin when compared in phase III clinical trials. Some have demonstrated improvements in progression-free survival, but only topotecan plus cisplatin has demonstrated an improvement in overall survival. This benefit is most apparent in patients who have a long disease-free interval from primary therapy and who have not received prior cisplatin as a radiosensitizer.
- 10 July 2007
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (20) , 2966-2974
Management of Metastatic Cervical Cancer: Review of the Literature
This article reviews the English-language literature concerning chemotherapy for advanced, recurrent, or metastatic cervix carcinoma. Specifically, it reviews the available literature for active single agents, doublets, triplets, and multiple drug combination chemotherapy. Until recently, single-agent cisplatin was the drug of choice in metastatic cervix cancer. Various doublets, triplets, and quartlets have been reported to have higher objective response rates than single-agent cisplatin when compared in phase III clinical trials. Some have demonstrated improvements in progression-free survival, but only topotecan plus cisplatin has demonstrated an improvement in overall survival. This benefit is most apparent in patients who have a long disease-free interval from primary therapy and who have not received prior cisplatin as a radiosensitizer.
- Open Access
- 31 December 2006
- Published by Elsevier in Molecular Therapy
- Vol. 13, S281
729. Phase I Trial of Intraperitoneal (IP) Administration of a Measles Virus (MV) Strain Expressing the Human Carcinoembryonic Antigen (CEA) in Ovarian Cancer Patients
- 31 December 2006
- Published by Elsevier in Molecular Therapy
- Vol. 13, S281
Open Access729. Phase I Trial of Intraperitoneal (IP) Administration of a Measles Virus (MV) Strain Expressing the Human Carcinoembryonic Antigen (CEA) in Ovarian Cancer Patients
- 1 November 2005
- Published by Elsevier in Gynecologic Oncology
- Vol. 99 (2) , 339-342
Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: A Gynecologic Oncology Group study
- 1 November 2005
- Published by Elsevier in Gynecologic Oncology
- Vol. 99 (2) , 339-342
Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: A Gynecologic Oncology Group study
- 1 November 2003
- Published by Springer Nature in Current Oncology Reports
- Vol. 5 (6) , 468-472
Current research directions for locally advanced cervix cancer
Chemoradiotherapy with either weekly doses of cisplatin or the combination of 5-fluorouracil and cisplatin has become the standard of therapy for patients with locally advanced cervix cancer. Recently reported studies that are directed at improvements in radiation treatment planning, improved tissue oxygenation, and neoadjuvant chemotherapy are likely to lead to improvements in therapy. Nonsurgical preoperative staging with positron emission tomography and sentinel lymph node evaluation could result in effective surgical staging, or even nonsurgical staging, more accurate radiation treatment planning, and improved local and systemic control with a reduction in short-term and long-term morbidity in the treatment of locally advanced cervix cancer. Well-designed, randomized, prospective clinical trials are needed for a more thorough evaluation of these preliminary findings and to set research directions for the next several years.
- 1 November 2003
- Published by Springer Nature in Current Oncology Reports
- Vol. 5 (6) , 468-472
Current research directions for locally advanced cervix cancer
Chemoradiotherapy with either weekly doses of cisplatin or the combination of 5-fluorouracil and cisplatin has become the standard of therapy for patients with locally advanced cervix cancer. Recently reported studies that are directed at improvements in radiation treatment planning, improved tissue oxygenation, and neoadjuvant chemotherapy are likely to lead to improvements in therapy. Nonsurgical preoperative staging with positron emission tomography and sentinel lymph node evaluation could result in effective surgical staging, or even nonsurgical staging, more accurate radiation treatment planning, and improved local and systemic control with a reduction in short-term and long-term morbidity in the treatment of locally advanced cervix cancer. Well-designed, randomized, prospective clinical trials are needed for a more thorough evaluation of these preliminary findings and to set research directions for the next several years.